A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
← catalyst calendarNCT04078295 · readout in 224 d
Sponsored by Eisai Co., Ltd. (industry) · 4523.T — their whole pipeline →. With Ono Pharmaceutical Co., Ltd..
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
125actual
Sites
19
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-05 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2019-09-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Neoplasms
Interventions
- Drug: E7389-LF
- Drug: Nivolumab — also filed as ONO-4538
Primary outcomes
what the primary-completion date above is the date OFPhase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)
measured Baseline up to Cycle 1 (Cycle length is equal to [=] up to 28 days)
Phase 2: ORR
measured Baseline up to End of Treatment (Up to approximately 79 months)
Publications
- PMID 39516370 — linked by the registry
- PMID 38295160 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed